Kanawha Capital Management LLC Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

Kanawha Capital Management LLC raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 9.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 274,435 shares of the biopharmaceutical company's stock after buying an additional 24,026 shares during the quarter. Kanawha Capital Management LLC's holdings in Pfizer were worth $6,954,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. First Bank & Trust grew its holdings in shares of Pfizer by 4.6% during the 1st quarter. First Bank & Trust now owns 69,478 shares of the biopharmaceutical company's stock worth $1,761,000 after purchasing an additional 3,063 shares in the last quarter. FSM Wealth Advisors LLC grew its holdings in shares of Pfizer by 8.6% during the 1st quarter. FSM Wealth Advisors LLC now owns 16,755 shares of the biopharmaceutical company's stock worth $425,000 after purchasing an additional 1,330 shares in the last quarter. WCM Investment Management LLC grew its holdings in shares of Pfizer by 8.7% during the 1st quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after purchasing an additional 10,051 shares in the last quarter. Sippican Capital Advisors grew its holdings in shares of Pfizer by 63.4% during the 1st quarter. Sippican Capital Advisors now owns 67,627 shares of the biopharmaceutical company's stock worth $1,714,000 after purchasing an additional 26,230 shares in the last quarter. Finally, Rossby Financial LCC grew its holdings in shares of Pfizer by 6.1% during the 1st quarter. Rossby Financial LCC now owns 9,322 shares of the biopharmaceutical company's stock worth $236,000 after purchasing an additional 538 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Pfizer stock traded up $0.13 during midday trading on Friday, reaching $25.45. The stock had a trading volume of 27,104,580 shares, compared to its average volume of 41,722,894. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm's 50-day moving average price is $23.72 and its 200 day moving average price is $24.82. The firm has a market capitalization of $144.66 billion, a PE ratio of 18.44, a P/E/G ratio of 0.92 and a beta of 0.58. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.82 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.76%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is presently 124.64%.

Analysts Set New Price Targets

PFE has been the topic of several research analyst reports. TD Cowen reduced their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research note on Tuesday, April 22nd. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. BMO Capital Markets lowered their target price on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Finally, UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.